Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Actavis, Ironwood mount second DTC push for GI med Linzess

With Actavis and Ironwood's first DTC campaign for GI med Linzess, the goal was to help patients identify irritable bowel syndrome with constipation and chronic idiopathic constipation by clearly communicating the symptoms. Now that the team is back with its sophomore DTC effort, the goal is to encourage patients to find a solution to their problems. A branded, prescription solution.

Mylan makes a pass at Perrigo with $205-per-share buyout offer

Generics specialist Mylan has zeroed in on the big buyout everyone's been waiting for. The Pittsburgh-based drugmaker offered $205 per share for Perrigo, the over-the-counter drugmaker that just closed its own $4.5 billion deal for Belgium's Omega Pharma.

Watch out for a two-front hep C price war when Merck's combo hits

Think we've seen a hepatitis C drug price war? Think again. This first round of pay-to-play formulary deals may pale in comparison to what's coming next year, as Merck & Co. gets closer to launching its two-drug combo pill.

Should 500K more young people be on statins? Guidelines say yes, JAMA reports

If physicians followed new cholesterol guidelines for statin use, almost half a million young people in the U.S. would be prescribed a statin, a JAMA Pediatrics study concludes.

No real rationale for rising cancer drug prices, JAMA researchers conclude

A recent analysis by National Institutes of Health researchers found that cancer drug prices aren't exactly linked to drug results. In fact, the study concludes, drugmakers are simply charging "what the market will bear."

Shire's Lialda, Gattex are hedge funder's latest patent targets

Hedge fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics drug, Bass asked the U.S. Patent and Trademark Office to reconsider coverage on two Shire meds, Lialda and Gattex.

Why didn't J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says

Why didn't Johnson & Johnson buy Pharmacyclics? Good question--and one The Wall Street Journal posed to CEO Alex Gorsky in a recent interview in Tokyo.

Amgen CEO Bradway collects a $14M pay package on record-breaking revenue

In a year when several of his peers won big payoffs for one extraordinary reason or another, Amgen CEO Robert Bradway earned just about as much as he had the previous year, give or take a few hundred thousand. Small comfort--though some comfort, perhaps--to the thousands of employees facing job cuts as Amgen prepares for biosimilar competition to its top-selling meds.

GSK shingles shot might trump Merck's Zostavax, analysts say

Though GlaxoSmithKline is still waiting on late-stage results from its shingles vaccine, HZ/su, Cowen & Co. analysts say the GSK shot may just be better than Merck's Zostavax.

India likely to extend price caps to more HIV, TB meds: Reuters

After stirring up protest by expanding its list of drugs subject to price caps late last year, India is considering adding more to the list. This time, health officials are likely to add more drugs that treat HIV and tuberculosis, Reuters reports.